Achieve Announces Positive Cytisine Data Demonstrating No Clinically Significant Drug-Drug Interaction
Achieve Announces Positive Cytisine Data Demonstrating No Clinically Significant Drug-Drug Interaction |
[26-June-2018] |
SEATTLE and VANCOUVER, British Columbia, June 26, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company, today announced positive results from a series of drug metabolism, drug-drug interaction and transporter studies with cytisine, the Company's product candidate being evaluated as an aid to smoking cessation.
The study demonstrated that cytisine has no clinically significant interaction with any of the hepatic enzymes commonly responsible for drug metabolism nor clinically significant interaction with drug transporters. This suggests that cytisine may be administered with other medications without the need to modify the dose of the co-administered drug. Dr. Anthony Clarke, Chief Scientific Officer of Achieve commented: "We are very pleased with the results of these detailed studies. Smokers are as likely as anyone to take medications for a range of conditions. These results suggest that cytisine is unlikely to interfere with their ability to take other medications safely, and should help to minimize restrictions on the eligibility of subjects in our forthcoming clinical trials expected to commence later this year." About Achieve & Cytisine Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Two prior, large-scale Phase 3 clinical studies of cytisine, with favorable outcomes, have been successfully completed in over 2,000 patients. The TASC trial was a 740 patient, double-blind, placebo controlled trial conceived by Professor Robert West at University College London and funded by the U.K. National Prevention Research Initiative. The CASCAID trial was a 1,310 patient, single-blind, non-inferiority trial comparing cytisine to nicotine replacement therapy (NRT). The CASCAID trial was conceived by Dr. Natalie Walker, National Institute for Health Innovation, University of Auckland and funded by the Health Research Council of New Zealand. Both trials were published in the New England Journal of Medicine. Forward Looking Statements Achieve Contact 1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2011, Geneva: World Health Organization, 2011.
SOURCE Achieve Life Sciences, Inc. | ||
Company Codes: NASDAQ-SMALL:ACHV |
© 2018 PR Newswire. All Rights Reserved.
#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}